![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CRTC2 |
Gene summary for CRTC2 |
![]() |
Gene information | Species | Human | Gene symbol | CRTC2 | Gene ID | 200186 |
Gene name | CREB regulated transcription coactivator 2 | |
Gene Alias | TORC-2 | |
Cytomap | 1q21.3 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q53ET0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
200186 | CRTC2 | LZE4T | Human | Esophagus | ESCC | 5.77e-07 | 1.90e-01 | 0.0811 |
200186 | CRTC2 | LZE7T | Human | Esophagus | ESCC | 2.21e-04 | 2.70e-01 | 0.0667 |
200186 | CRTC2 | LZE20T | Human | Esophagus | ESCC | 6.06e-05 | 1.05e-01 | 0.0662 |
200186 | CRTC2 | LZE24T | Human | Esophagus | ESCC | 3.62e-13 | 3.34e-01 | 0.0596 |
200186 | CRTC2 | LZE6T | Human | Esophagus | ESCC | 9.67e-06 | 1.07e-01 | 0.0845 |
200186 | CRTC2 | P1T-E | Human | Esophagus | ESCC | 1.07e-05 | 4.14e-01 | 0.0875 |
200186 | CRTC2 | P2T-E | Human | Esophagus | ESCC | 3.32e-13 | 2.38e-01 | 0.1177 |
200186 | CRTC2 | P4T-E | Human | Esophagus | ESCC | 2.57e-14 | 7.55e-02 | 0.1323 |
200186 | CRTC2 | P5T-E | Human | Esophagus | ESCC | 5.15e-14 | 9.09e-02 | 0.1327 |
200186 | CRTC2 | P8T-E | Human | Esophagus | ESCC | 6.46e-13 | 2.92e-01 | 0.0889 |
200186 | CRTC2 | P9T-E | Human | Esophagus | ESCC | 9.38e-14 | 2.33e-01 | 0.1131 |
200186 | CRTC2 | P10T-E | Human | Esophagus | ESCC | 2.59e-15 | 1.88e-01 | 0.116 |
200186 | CRTC2 | P11T-E | Human | Esophagus | ESCC | 1.11e-13 | 3.47e-01 | 0.1426 |
200186 | CRTC2 | P12T-E | Human | Esophagus | ESCC | 2.02e-12 | 1.66e-01 | 0.1122 |
200186 | CRTC2 | P15T-E | Human | Esophagus | ESCC | 5.17e-18 | 3.95e-01 | 0.1149 |
200186 | CRTC2 | P16T-E | Human | Esophagus | ESCC | 2.38e-14 | 1.39e-01 | 0.1153 |
200186 | CRTC2 | P17T-E | Human | Esophagus | ESCC | 1.43e-06 | 2.03e-01 | 0.1278 |
200186 | CRTC2 | P20T-E | Human | Esophagus | ESCC | 4.14e-17 | 3.09e-01 | 0.1124 |
200186 | CRTC2 | P21T-E | Human | Esophagus | ESCC | 1.10e-16 | 2.29e-01 | 0.1617 |
200186 | CRTC2 | P22T-E | Human | Esophagus | ESCC | 4.79e-15 | 1.41e-01 | 0.1236 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
GO:00059969 | Esophagus | ESCC | monosaccharide metabolic process | 159/8552 | 257/18723 | 1.11e-07 | 1.81e-06 | 159 |
GO:00193189 | Esophagus | ESCC | hexose metabolic process | 147/8552 | 237/18723 | 2.63e-07 | 3.94e-06 | 147 |
GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
GO:00510918 | Esophagus | ESCC | positive regulation of DNA-binding transcription factor activity | 155/8552 | 260/18723 | 3.83e-06 | 4.14e-05 | 155 |
GO:00060069 | Esophagus | ESCC | glucose metabolic process | 119/8552 | 196/18723 | 1.51e-05 | 1.36e-04 | 119 |
GO:00439662 | Esophagus | ESCC | histone H3 acetylation | 43/8552 | 61/18723 | 7.57e-05 | 5.67e-04 | 43 |
GO:00160514 | Esophagus | ESCC | carbohydrate biosynthetic process | 117/8552 | 202/18723 | 2.96e-04 | 1.79e-03 | 117 |
GO:00463643 | Esophagus | ESCC | monosaccharide biosynthetic process | 52/8552 | 82/18723 | 9.03e-04 | 4.61e-03 | 52 |
GO:00512623 | Esophagus | ESCC | protein tetramerization | 54/8552 | 87/18723 | 1.50e-03 | 7.06e-03 | 54 |
GO:19019987 | Esophagus | ESCC | toxin transport | 28/8552 | 40/18723 | 1.61e-03 | 7.50e-03 | 28 |
GO:00193193 | Esophagus | ESCC | hexose biosynthetic process | 49/8552 | 78/18723 | 1.69e-03 | 7.81e-03 | 49 |
GO:00512592 | Esophagus | ESCC | protein complex oligomerization | 130/8552 | 238/18723 | 3.29e-03 | 1.36e-02 | 130 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa041529 | Oral cavity | OSCC | AMPK signaling pathway | 71/3704 | 121/8465 | 6.29e-04 | 1.86e-03 | 9.49e-04 | 71 |
hsa049317 | Oral cavity | OSCC | Insulin resistance | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
hsa05166113 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0415212 | Oral cavity | OSCC | AMPK signaling pathway | 71/3704 | 121/8465 | 6.29e-04 | 1.86e-03 | 9.49e-04 | 71 |
hsa0493112 | Oral cavity | OSCC | Insulin resistance | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
hsa05166210 | Oral cavity | LP | Human T-cell leukemia virus 1 infection | 100/2418 | 222/8465 | 8.94e-08 | 1.29e-06 | 8.35e-07 | 100 |
hsa0516638 | Oral cavity | LP | Human T-cell leukemia virus 1 infection | 100/2418 | 222/8465 | 8.94e-08 | 1.29e-06 | 8.35e-07 | 100 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CRTC2 | SNV | Missense_Mutation | c.1496N>T | p.Pro499Leu | p.P499L | Q53ET0 | protein_coding | deleterious(0.03) | benign(0) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD | |
CRTC2 | SNV | Missense_Mutation | rs752412661 | c.356N>A | p.Arg119His | p.R119H | Q53ET0 | protein_coding | deleterious(0.04) | benign(0) | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
CRTC2 | SNV | Missense_Mutation | c.434N>C | p.Arg145Thr | p.R145T | Q53ET0 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CRTC2 | SNV | Missense_Mutation | c.856N>T | p.Pro286Ser | p.P286S | Q53ET0 | protein_coding | deleterious(0.01) | probably_damaging(0.948) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
CRTC2 | SNV | Missense_Mutation | c.518C>G | p.Ser173Cys | p.S173C | Q53ET0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0HW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
CRTC2 | SNV | Missense_Mutation | novel | c.1789C>G | p.Pro597Ala | p.P597A | Q53ET0 | protein_coding | tolerated(0.07) | benign(0.001) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CRTC2 | deletion | Frame_Shift_Del | novel | c.1763_1764delNN | p.Glu588GlyfsTer28 | p.E588Gfs*28 | Q53ET0 | protein_coding | TCGA-BH-A0DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
CRTC2 | SNV | Missense_Mutation | c.2032C>A | p.Leu678Met | p.L678M | Q53ET0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CRTC2 | SNV | Missense_Mutation | novel | c.1881C>A | p.Phe627Leu | p.F627L | Q53ET0 | protein_coding | tolerated(1) | benign(0.037) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CRTC2 | SNV | Missense_Mutation | novel | c.559A>G | p.Thr187Ala | p.T187A | Q53ET0 | protein_coding | tolerated(0.83) | benign(0.072) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
200186 | CRTC2 | KINASE | PKI-587 | GEDATOLISIB | ||
200186 | CRTC2 | KINASE | tacrolimus | TACROLIMUS | 26644205 | |
200186 | CRTC2 | KINASE | N/A | |||
200186 | CRTC2 | KINASE | XL765 | |||
200186 | CRTC2 | KINASE | INK128 | SAPANISERTIB | ||
200186 | CRTC2 | KINASE | NVP-BEZ235 | DACTOLISIB | ||
200186 | CRTC2 | KINASE | cyclosporine | CYCLOSPORINE | 26644205 |
Page: 1 |